Michael McElhaugh

Michael McElhaugh

Former Interim President and Chief Executive OfficeratArbutus Biopharma· In proxies 2022–2025

Pay in FY2025+70% from the year before · Arbutus Biopharma stock +47.1% the same year

Michael McElhaugh was paid $3.6M in FY2025 (Dec), up 70%. Arbutus Biopharma stock rose 47.1% that year.

Pay$100 in the stock at the end of FY21 → $115
Pay is from the Summary Compensation Table of each Arbutus Biopharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Arbutus BiopharmaPublic company · 4 yr
    • Former Interim President and Chief Executive Officer2022 – Present · 4 yrStock in role +12%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?